Published in:
01-02-2006 | Poster presentation
The erythropoietin neuroprotective effect: assessment in coronary artery bypass graft surgery (TENPEAKS) – a randomized, double-blind, placebo-controlled, proof-of-concept clinical trial
Authors:
G Haljan, A Maitland, A Buchan, M King, J Haigh, B Culleton, P Faris, D Zygun
Published in:
Critical Care
|
Special Issue 1/2006
Login to get access
Excerpt
Human recombinant erythropoietin (rh-Epo) may be a potent neuroprotectant [
1]. It is approved in Canada to reduce blood transfusions in coronary artery bypass graft (CABG) surgery, which is complicated by neurocognitive dysfunction (NCD) in 50–80% of patients at discharge, 10–36% at 6 weeks and 42% at 5 years [
2]. We conducted a randomized, double-blind, placebo-controlled study in 32 first-time CABG patients to investigate the feasibility and safety of three doses of rh-Epo with the ultimate goal of reducing NCD in patients following CABG. …